Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA
09:11am, Friday, 21'st Nov 2025
Zymeworks is gaining momentum as Ziihera shows strong Phase III data in HER2+ gastroesophageal adenocarcinoma, supporting growth and de-risking the investment. ZYME's royalty-based business model with
Zymeworks: A Lot Of Moving Parts
02:10pm, Wednesday, 19'th Nov 2025
This article revisits Zymeworks Inc. following significant new trial data released this week. This triggered a 30% rally in ZYME stock on Monday, even as most of any future revenues will accrue to par
Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript
05:08pm, Tuesday, 18'th Nov 2025
Zymeworks Inc. ( ZYME ) Shareholder/Analyst Call November 18, 2025 8:30 AM EST Company Participants Shrinal Inamdar - Director of Investor Relations Kenneth Galbraith - Chairman of the Board, CEO & Pr
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
01:01am, Tuesday, 18'th Nov 2025
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pip
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipe
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
02:43pm, Monday, 17'th Nov 2025
Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in com
Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity
01:45pm, Monday, 17'th Nov 2025
Zymeworks Inc. (ZYME) surged after positive Phase 3 results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma, expanding its FDA-approved indications. ZYME's partnership-driven m
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
12:09pm, Monday, 17'th Nov 2025
Zymeworks Inc. (NASDAQ: ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
08:10am, Monday, 17'th Nov 2025
The companies' drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.
VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Reviewing Comera Life Sciences (NASDAQ:CMRA) & Zymeworks (NYSE:ZYME)
04:32am, Monday, 17'th Nov 2025
Zymeworks (NYSE: ZYME - Get Free Report) and Comera Life Sciences (NASDAQ: CMRA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two c
Zymeworks (NASDAQ:ZYME) and Addex Therapeutics (OTCMKTS:ADDXF) Head to Head Survey
03:44am, Saturday, 15'th Nov 2025
Addex Therapeutics (OTCMKTS:ADDXF - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies ba
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
12:06am, Friday, 07'th Nov 2025
Zymeworks Inc. ( ZYME ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Shrinal Inamdar - Director of Investor Relations Leone Patterson - Executive VP and Chief Business & Fin
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
06:36pm, Thursday, 06'th Nov 2025
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.39 per share a year ago.
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
04:05pm, Thursday, 06'th Nov 2025
Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), presented at the AACR-NCI-EORTC Conference First patient dosed in Phase 1 clinical trial of Z
